Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc ADR
(NQ:
AZN
)
65.63
+1.37 (+2.13%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc ADR
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
59
60
Next >
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
February 28, 2024
A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year.
Via
Benzinga
3 Inflation-Resilient Stocks to Weather the Economic Turbulence
February 28, 2024
These are the undervalued inflation-resilient stocks to buy as they represent companies that have strong fundamentals.
Via
InvestorPlace
EXCLUSIVE: Vivani Medical Says Weight Loss/Diabetes Implant At Par With Novo Nordisk's Famed Injectable Wegovy/Ozempic, Animal Studies Shows
February 28, 2024
Vivani Medical unveils preclinical data on NPM-115, a twice-yearly exenatide subdermal implant for weight loss. Achieving a 20% reduction in high-fat diet-induced obese mice, comparable to Novo...
Via
Benzinga
Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors
February 26, 2024
Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new obesity drugs and pushing the company's shares 30% higher.
Via
Benzinga
Check Out What Whales Are Doing With AZN
February 16, 2024
Via
Benzinga
Earnings Scheduled For February 8, 2024
February 08, 2024
Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million.
Via
Benzinga
Earnings Outlook For AstraZeneca
February 07, 2024
Via
Benzinga
MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA
February 23, 2024
From
AstraZeneca
Via
Business Wire
Move Over Magnificent 7, Say Hello to the GRANOLAS
February 22, 2024
Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods.
Via
InvestorPlace
Why AstraZeneca Stock Is Trading Higher Tuesday
February 20, 2024
FDA greenlights AstraZeneca's Tagrisso combo for advanced EGFRm NSCLC. FLAURA2 Phase 3 trial results reveal a 38% reduction in progression risk with Tagrisso plus chemo, outperforming monotherapy....
Via
Benzinga
Exposures
Product Safety
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer
February 19, 2024
From
AstraZeneca
Via
Business Wire
TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial
February 19, 2024
From
AstraZeneca
Via
Business Wire
Cruising For A Bruising
February 18, 2024
We’re currently living in the soft landing, and it is pleasant indeed. But inflation numbers at the start of the year have put us on notice. Like the Magnificent Seven, hopes of a sustained soft...
Via
Talk Markets
Topics
Economy
Exposures
Economy
Interest Rates
Week In Review: LianBio To Close Operations; Will Pay $528 Million To Shareholders
February 17, 2024
LianBio, a Princeton-Shanghai biotech, has decided to call it quits. LianBio plans to stop all of its operations by the end of 2024, and it will distribute a $4.80 dividend/share ($528 million) to its...
Via
Talk Markets
TAGRISSO® (osimertinib) with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer
February 16, 2024
From
AstraZeneca
Via
Business Wire
7 Contrarian Biotech Stocks to Consider Amid Sector Weakness
February 15, 2024
Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts.
Via
InvestorPlace
7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution
February 14, 2024
Obesity drug sales boomed in 2023 and will continue in 2024. That could make these weight loss stocks even more attractive.
Via
InvestorPlace
Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report
February 13, 2024
Kerrisdale Capital has released a short report, making clear why it is betting against ALT stock. Here's why Altimmune is likely in trouble.
Via
InvestorPlace
Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.
February 13, 2024
There's more for investors to get excited about in the biopharma world than just weight-loss drugs.
Via
The Motley Fool
This Analyst Slightly Lowers AstraZeneca Forecast Amid Earnings Concerns, Although Still Bullish on Future Growth Potential
February 12, 2024
AstraZeneca reported Q4 2023 sales of $12.02B, up 7%, below consensus. Excluding COVID-19 drugs, revenue increased by 16%. Core EPS was $1.45, missing consensus. BMO Capital maintains Outperform...
Via
Benzinga
Exposures
COVID-19
AstraZeneca Leads The FTSE Lower On Barclay’s Downgrade
February 12, 2024
The pharmaceutical sector saw a decline of 1.6%, with AstraZeneca dropping 2.4% after Barclays lowered its price target for the stock.
Via
Talk Markets
From Slack To Surveillance: Here's How Companies Monitor Your Communications With AI
February 10, 2024
In a move reminiscent of George Orwell's surveillance dystopia, companies are now deploying artificial intelligence (AI) to monitor communications on platforms like Slack and Microsoft Teams.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Got $5,000? These 3 Stocks Are Near Their 52-Week Lows and Are Underrated Buys
February 10, 2024
These stocks all trade at less than 17 times their future expected earnings.
Via
The Motley Fool
AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript
February 08, 2024
AZN earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
How Cytokinetics Overcame Two Setbacks And Doubled Its Stock Price Over A Month
February 08, 2024
Cytokinetics is looking to take on Bristol Myers Squibb in treating a heart disease.
Via
Investor's Business Daily
Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
February 08, 2024
Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results.
Via
Benzinga
AstraZeneca Stock Tumbles After Q4 Performance - Here's Why
February 08, 2024
AstraZeneca Q4 2023: $12.02 billion sales, 7% Y/Y growth, fueled by global demand for cancer drugs. Excluding COVID-19 meds, revenue rises 16%. CEO Soriot projects low double-digit growth in 2024.
Via
Benzinga
Exposures
COVID-19
AstraZeneca Downgraded On "Underwhelming" Q4 Earnings
February 08, 2024
AZN stock took a header early Thursday after a mixed Q4 report and a downgrade to sell on "thoroughly underwhelming" results.
Via
Investor's Business Daily
AstraZeneca Full year and Q4 2023 Financial Results
February 08, 2024
From
AstraZeneca
Via
Business Wire
AstraZeneca expands US manufacturing footprint to accelerate ambitions in next-generation cell therapy discovery and development
February 06, 2024
From
AstraZeneca
Via
Business Wire
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
59
60
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.